Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.PLRX stock is showing notable weakness. Check out the latest moves here.Pliant Therapeutics on Thursday released interim data from its Phase 1 dose escalation trial of PLN-101095.The trial evaluated PLN-101095 in combination with Merck & Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metasta ...